Deciphera Pharmaceuticals, which is developing kinase inhibitors for solid tumors, raised $128 million by offering 7.5 million shares at $17, the high end of the range of $15 to $17. Deciphera Pharmaceuticals plans to list on the Nasdaq under the symbol DCPH. J.P. Morgan and Piper Jaffray acted as lead managers on the deal.
